ALNY news, real time ALNY stock news, Alnylam Pharmaceuticals Inc news today

News

ALNY

403.11

+1.79%

7.07

Noteworthy ETF Inflows: CGGR, TDG, ALNY, DHI

NASDAQ · 6h ago

PeptiDream Achieves Preclinical Milestone in siRNA Delivery Collaboration with Alnylam

Reuters · 1d ago

Harbor Long-Term Growers ETF Q3 Takeaways From Momentum In Artificial Intelligence

Seeking Alpha · 1d ago

Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today

Benzinga · 1d ago

Alnylam To Expand Massachusetts Manufacturing Facility With $250 Million Investment

NASDAQ · 2d ago

Alnylam to invest $250M to expand manufacturing facility in Massachusetts

TipRanks · 2d ago

Alnylam Pharma To Invest $250M To Advance siRNA Enzymatic-Ligation Manufacturing Facility

Benzinga · 2d ago

Alnylam Invests $250 Million to Expand RNAi Drug Manufacturing in Massachusetts

Reuters · 2d ago

ALNYLAM PHARMACEUTICALS INC - NEW CAPABILITIES OPERATIONAL BY LATE 2027

Reuters · 2d ago

ALNYLAM TO INVEST $250 MILLION TO ADD ENZYMATIC LIGATION PLATFORM TO U.S. MANUFACTURING FACILITY TO MEET GROWING GLOBAL DEMAND FOR RNAI THERAPEUTICS

Reuters · 2d ago

Health Canada Approves Alnylam's AMVUTTRA For ATTR Cardiomyopathy

Benzinga · 3d ago

ALNYLAM ANNOUNCES HEALTH CANADA APPROVAL OF AMVUTTRA® (VUTRISIRAN), THE FIRST AND ONLY RNAI THERAPEUTIC FOR THE TREATMENT OF CARDIOMYOPATHY IN ADULT PATIENTS WITH ATTR AMYLOIDOSIS

Reuters · 3d ago

Is Alnylam (ALNY) Using Nasdaq 100 Inclusion To Quietly Redefine Its Capital Allocation Playbook?

Simply Wall St · 3d ago

Oversold Conditions For Alnylam Pharmaceuticals (ALNY)

NASDAQ · 4d ago

Validea Detailed Fundamental Analysis - ALNY

NASDAQ · 4d ago

Alnylam Pharmaceuticals Is Maintained at Market Perform by Leerink Partners

Dow Jones · 4d ago

Alnylam Pharmaceuticals Price Target Cut to $351.00/Share From $370.00 by Leerink Partners

Dow Jones · 4d ago

Leerink Partners Maintains Market Perform on Alnylam Pharmaceuticals, Lowers Price Target to $351

Benzinga · 4d ago

Seagate, Western Digital among additions to Nasdaq-100 on 12/22

TipRanks · 4d ago

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Novan (NOVN) and Dyadic International (DYAI)

TipRanks · 4d ago

Webull provides a variety of real-time ALNY stock news. You can receive the latest news about Alnylam Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.

About ALNY

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.